The Company generated approximately $4.0 million of cash from operations for the year despite significant investments in inventory to address supply chain issues, a substantial increase versus $2.3 million in the prior year. The Company ended the year with cash on hand of $9.7 million, and $4 million available under existing lines of credit.

All amounts are in US dollars, unless specified otherwise, and results, with the exception of Adjusted EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS").

Results of Operations for the Year ended December 31, 2023

Hamilton Thorne sales increased 16% to $67,225,476 for the year-ended December 31, 2023, an increase of $9,047,409 from $58,178,067 during the previous year. Sales increased primarily due to the addition of Microptic sales, a return to more normalized operations as compared to supply chain and logistics issues affecting results in the prior year, along with continued growth, despite a slowdown in China. Constant currency sales were up 14%. Organic growth was 9% for the year.

Service, Software, and Consumable sales were up 22% for the year compared to last year. Consumable sales in 2023 outpaced the Company’s overall growth despite being affected by the recall of certain products by one of the Company’s contract manufacturers.

Sales of equipment were 8% higher than last year. During the year the Company faced a significant reduction in equipment sales to China due to several factors including the economic slowdown in China, the enforcement of “buy China” policies, combined with the emergence of local competition, and delays in regulatory clearance, although we have seen growth in China stabilizing in Q4.

Gross profit for the year increased 16% or $4,770,435 to $33,850,565 in the year-ended December 31, 2023, compared to $29,080,130 in the previous year, primarily as a function of sales growth, and product mix. Gross profit as a percentage of sales was 50.4% compared to 50.0% in prior year, due to increased sales of higher margin proprietary equipment, branded consumables, and additional direct sales of products, partially offset by the higher material costs caused by the global inflationary environment.

Operating expenses, excluding expenses related to acquisition and M&A activities, increased 21% to $31,284,964 for the year-ended December 31, 2023, up from $25,810,860 for the previous year, primarily due to the addition of Microptic expenses for the full year, continued investments in sales and customer support resources, increased depreciation and amortization due to investment in capacity expansion, and increased travel and tradeshow expense as activity continued to return to pre-pandemic levels. The global inflationary situation that impacted our cost of goods sold and personnel costs during 2022, continued to a somewhat lesser extent in 2023, contributing to the increase in operating expenses.

Net interest expense increased $939,021 from $433,834 to $1,372,855 for the year-ended December 31, 2023 versus the prior year, primarily due to increased term debt to finance the Microptic (November 2022) and Gynetics acquisitions (October 2023), and the higher use of bank line of credit to fund working capital, partially offset by reduction in other term debts due to principal repayment, and interest earned on the Company’s cash balances.

Net loss for 2023 was $607,022 versus a net income of $1,910,594 for the prior year, primarily due to increased operating expense, including M&A and other non-recurring expenses, higher depreciation and amortisation and interest expenses, partially offset by increased sales and gross profit.

Adjusted EBITDA for the year-ended December 31, 2023 increased 14% to $11,518,504 (or 17.1% of Sales) versus $10,085,600 in the prior year, primarily due to increased sales and gross profit offset by planned increases in operating expenses.

Results of Operations for the Fourth Quarter ended December 31, 2023

For the three months ended December 31, 2023, sales were up 12% from $16,427,918 to $18,443,651, or up 8% on constant currency, organic sales were up 7%. Gross profit was up 7% to $9,191,922 versus $8,618,316 for the prior year. Gross profit percentage decreased from 52.5% to 49.8% for the quarter, primarily due to product mix and increased distributor sales of our own branded products. Operating expenses, excluding expenses related to acquisition and M&A activities, increased 13% to $7,597,887 for the quarter, up from $6,723,220 from the previous year quarter, primarily due to the addition of Microptic and Gynetics expenses for the full quarter, increased staffing and sales and marketing expense.

In the fourth quarter of 2023 the Company’s net Income was $540,237 while Adjusted EBITDA increased 21% to $3,697,432 (or 20.0% of sales) versus net income of $980,391 and Adjusted EBITDA of $3,039,477 for the prior year fourth quarter. These changes were due primarily to increased sales and gross profits offset by increased operating expenses, interest and nonrecurring non-operating expenses.

See the Company’s Management Discussion and Analysis for the periods covered for further information and a reconciliation of Adjusted EBITDA to Net Income.

Outlook

Dr. Torchilin continued, “Since joining the Company in January, I have been deeply impressed by the dedication of our talented colleagues across the globe to supporting our customers with best in class products and services, and by the commitment of our team to continued improvements in the field of infertility treatments and playing our part in helping millions of families to fulfill their dreams of having a baby. We continue to feel that our Company is in a strong position as demand for our products and services remains solid based on the positive trends in our field. We believe that somewhat softer organic growth in the last couple of quarters is temporary and the Company should return to double digit organic growth in the first half of 2024, continuing through the longer term. We are expecting first quarter 2024 reported revenues of between $19.0 to 19.4M, with organic growth for the quarter of approximately 8%. For the full twelve months of 2024, we anticipate delivering between $78-$82M revenue, equivalent to 10-15% organic growth for the full year.

Francesco Fragasso, the Company’s Chief Financial Officer, added “In 2023, we made significant investments in our operations to facilitate long-term growth. Management is committed to EBITDA margin expansion and we anticipate tighter operating expense control in 2024, while continue to leverage our larger scale. We anticipate Q1 of 2024 to be our lowest EBITDA margin quarter in 2024 at approximately 18%, but in the range of 19.5% to 20.5% for the full year. Cash flow is expected to improve as the investment in expanding capacity has been completed and inventory will decrease in the following months.”

Commenting on the Company’s M&A activities, Dr. Torchilin stated, “We continue to focus on building Hamilton Thorne LTD into the premier company serving IVF/ART laboratories globally. We have an extensive pipeline and are actively working on multiple acquisition opportunities. With significant cash on hand and our unused line of credit, and further debt capacity, we are well positioned to continue to execute on our acquisition program.”

Conference Call

The Company has scheduled a conference call on Thursday, March 27, 2024 at 9:00 a.m. EDT to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1- 833-366-1126 in North America, or 1-412-317-0703 from other locations, and requesting the “Hamilton Thorne Call.” The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.

Financial Statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

The Company has included Adjusted EBITDA, Organic Growth, and Constant Currency as non-IFRS measures, which are used by management as measures of financial performance. See section entitled “Use of Non-IFRS Measures” and “Results of Operations” in the Company’s Management Discussion and Analysis for the periods covered for further information and a reconciliation of Adjusted EBITDA to Net Income.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.